公开(公告)号：US06525176B1

公开(公告)日：2003-02-25

申请号：US09612592

申请日：2000-07-07

Applicant: Vivian W. Lee ,  Kris P. Antonsen

Inventor： Vivian W. Lee ,  Kris P. Antonsen

IPC: C07K100

CPC classification number: C07K14/8125 ,  Y10S530/83

Abstract: A method for purifying human or other alpha-l proteinase inhibitor (&agr;1-PI) from a solution (which may be derived from the milk of a transgenic animal expressing the &agr;1-PI) which comprises contacting the solution with a cation exchange substrate under conditions sufficient to bind non-tg-&agr;1-PI contaminants to the substrate while not substantially binding tg &agr;1-PI to the substrate. Using the preferred embodiment, the purified tg &agr;1-PI contains as little as 40 pg non-&agr;1-PI-whey protein per mg total protein.

Abstract translation: 从溶液（其可以衍生自表达α1-PI的转基因动物的乳中）纯化人或其他α-1蛋白酶抑制剂（α1-P​​I）的方法，其包括在条件下使所述溶液与阳离子交换底物接触 足以将非tg-α1-PI污染物结合到基底上，而基本上不结合tgα1-PI。 使用优选的实施方案，纯化的tgα1-PI每mg总蛋白含有少至40pg非α1-PI-乳清蛋白。

公开(公告)号：US06194553B1

公开(公告)日：2001-02-27

申请号：US09036796

申请日：1998-03-09

Applicant: Vivian W. Lee ,  Kris P. Antonsen

Inventor： Vivian W. Lee ,  Kris P. Antonsen

IPC: C07K118

CPC classification number: C07K14/8125 ,  Y10S530/83

Abstract: A method for purifying human or other alpha-1 proteinase inhibitor (&agr;1-PI) from a solution (which may be derived from the milk of a transgenic animal expressing the &agr;1-PI) which comprises contacting the solution with a cation exchange substrate under conditions sufficient to bind non-tg-&agr;1-PI contaminants to the substrate while not substantially binding tg &agr;1-PI to the substrate. Using the preferred embodiment, the purified tg &agr;1-PI contains as little as 40 pg non-&agr;1-PI-whey protein per mg total protein.

Abstract translation: 从溶液（其可以衍生自表达α1-PI的转基因动物的乳）中纯化人或其他α-1蛋白酶抑制剂（α1-P​​I）的方法，其包括在条件下使该溶液与阳离子交换底物接触 足以将非tg-α1-PI污染物结合到基底上，而基本上不结合tgα1-PI。 使用优选的实施方案，纯化的tgα1-PI每mg总蛋白含有少至40pg非α1-PI-乳清蛋白。

公开(公告)号：US06391452B1

公开(公告)日：2002-05-21

申请号：US09118463

申请日：1998-07-17

Applicant: Kris P. Antonsen ,  Rajiv Nayar ,  Wei Wang ,  Margaret Caudle ,  Michael A. Shearer ,  Neville M. Concessio

Inventor： Kris P. Antonsen ,  Rajiv Nayar ,  Wei Wang ,  Margaret Caudle ,  Michael A. Shearer ,  Neville M. Concessio

IPC: B32B1502

CPC classification number: C07K14/70525 ,  A61K9/0043 ,  A61K9/1658 ,  A61K38/00 ,  Y10T428/2984

Abstract: The present invention relates to pharmaceutical compositions for delivery of drugs intended to reside in the nose, compositions for nasal administration of drugs, e.g., antiviral agents, and particularly antiviral agents comprising the human major rhinovirus receptor, also known as intercellular adhesion molecule-1 (ICAM-1); to methods of making said nasal drug compositions, and to an improved process for the removal of residual solvent from pharmaceutical matrices.

Abstract translation: 本发明涉及用于递送旨在存在于鼻中的药物的药物组合物，用于鼻内给药的组合物，例如抗病毒剂，特别是包含人类主要鼻病毒受体（也称为细胞间粘附分子-1）的抗病毒剂 ICAM-1）; 制备所述鼻用药物组合物的方法，以及用于从药物基质中除去残余溶剂的改进方法。